These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38437773)

  • 1. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
    Wu W; Lu X; Zhang L; Hong D
    Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
    J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-Analysis.
    Song Z; Zhang J; Xue T; Yang Y; Wu D; Chen Z; You W; Wang Z
    Front Neurol; 2021; 12():707723. PubMed ID: 34630283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
    Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
    Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
    Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
    Leta V; van Wamelen DJ; Aureli F; Metta V; Trivedi D; Cortelli P; Rodriguez-Blazquez C; Rizos A; Ray Chaudhuri K
    J Neural Transm (Vienna); 2023 Jul; 130(7):925-930. PubMed ID: 37036498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
    Harrison-Jones G; Marston XL; Morgante F; Chaudhuri KR; Castilla-Fernández G; Di Foggia V
    Eur J Neurol; 2023 Oct; 30(10):3132-3141. PubMed ID: 37489574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
    Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
    J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T; Schlegel E; Zingler S; Thiede HM
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
    St Onge E; Vanderhoof M; Miller S
    Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Ferreira JJ
    Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.